Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Cardiology > 268 NSTEMI > Flashcards

268 NSTEMI Flashcards

(93 cards)

Start Studying
1
Q

Topical or oral nitrates can be used when the pain has resolved or they may replace intravenous nitroglycerin when patient has been symptom free for how long?

A

12-24 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Most common etiology of coronary thrombosis

A

Plaque rupture

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Vulnerable plaques

A

Eccentric stenosis with scalloped or overhanging edges and a narrow neck
Lipid core with thin fibrous cap

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Genetic variant related to Inadequate response to clopidogrel

A

CYP450 involving 2C19

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Demonstrates the transient coronary spasm in Prinzmetal variant angina

A

Coronary angiography

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Main therapeutic agents in Prinzmetal Variant Angina

A

Nitrates and calcium channel blockers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Most dangerous manifestation of ischemic heart disease

A

Acute coronary syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Mode of action of nitrates

A

Venous vasodilation with concomitant reduction in LV end diastolic volume

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q 
A 50M complains of chest heaviness associated with shortness of breath and diaphoresis 5 hours PTC. He lost consciousness and pronounced dead at the ER. Which type of myocardial infarction will you classify the patient?
A. Type 1
B. Type 2
C. Type 3
D> Type 4
A

Type 3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

pathophysiology of NSTE-ACS

A

disruption of an unstable coronary plaque due to plaque rupture, erosion or a calcified protruding nodule tat leads to intracoronary arterial vasoconstriction, 2. coronary arterial vasoconstriction, 3. gradual intraluminal narrowing, 4. increased myocardial oxygen demand

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

most common etiology of coronary thrombosis

A

Plaque rupture

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

description of the vulnerable plaque

A

eccentric stenosis with scalloped or overhanging edge and narrow neck on coronary angiogrpahy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

True or false. Vulnerable plaques are composed of lipid rich core with thin fibrous cap

A

True.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

True or false. NSTE-ACS is based largely on clinical presentation.

A

True.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Typical chest discomfort.

A

one of three features: 1. occurrence at rest or with minimal exertion lasting more than 10 mins 2. of relatively recent onset within the prior 2 week and 3. a crescendo pattern, distinctly more severe, prolonged or frequent than previous episodes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Location of chest discomfort

A

substernal region, radiates to left arm, left shoulder, and/or superiorly to the neck and jaw

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

anginal equivalents

A

dyspnea, epigastric discomfort, nausea or weakness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

subset of patients who may present with anginal equivalent

A

women, elderly, patients with diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

ECG findings of NSTE ACS

A

deep t wave inversion of more than 0.3 mV;

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

True or false. New ST segment depression occurs in one third of patient with NSTE-ACS

A

True.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

minor elevations in cTn in patients without clinical history of myocardial ischemia

A

seen in patients with heart failure, myocarditis, pulmonary embolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

characteristic temporal rise and fall post onset of symptoms

A

Peaking 12-24 hrs post onset of symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Non cardiac or systemic causes of elevated cTn

A

pulmonary embolism, trauma, hypo or hyperthyroidism, renal failure, sepsis, shock, stroke, rhabdomyolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

when to take or repeat cardiac biomarkers

A

obtained at baseline and at 4-6 hour and 12 hours after presentation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
True or false. Patients with NSTE ACS should be placed at bed rest with continuous ECG monitoring for ST segment deviation and cardiac arrhytmias, preferably a specialized cardiac unit
True.
26
when is ambulation permitted in the patient with NSTE ACS
no recurrence of ischemia and does not develop an elevation of biomarker of necrosis for 12-24 hours
27
when is oxygen supplementation given
O2 sat less than 90% and or in those with heart failure and rales
28
absolute contraindication to nitrates
hypotension and recent use of PDE5 inhibitor within the 24 hr
29
how should nitrates be given
Nitroglycerin 03.-0.6 mg q 5mins apart
30
how to give nitroglycerin IV
10 ug/min every 3-5 mins until symptoms are relieved, or SBP falls to less than 90 mmHg or dose reaches 200 ug/min
31
max dose of nitroglycerin
200 ug/min
32
when is IV nitrate be shifted to oral
patient has been symptom free for 12-24 hrs
33
mainstay of anti ischemic treatment
beta blockers
34
target heart rate
50-60 bpm
35
when is beta blocker avoided
severe heart failure, low cardiac output, hypotension, active bronchospasm, high degree AV block
36
recommended for patients who have persistent symptoms or ECG signs of ischemia after treatment with full dose nitrates and beta blockers and in patients with contraindications to either drug class
calcium channel blockers like verapamil
37
add on medication if LDL C is not on target with statin
Ezetimibe 10 mg OD
38
drug that causes irreversible blockade of the platelet PY212 receptor
clopidogrel
39
loading and maintenance dose of clopidogrel
600 or 300 mg loading dose then 75 mg OD maintenance dose
40
relative reduction in cardiovascular death, MI, stroke compared to aspirin alone vs DAPT
20.00%
41
Drugs commonly used in intensive medical management of patients with UA and NSTE ACS
nitrates, beta blockers, calcium channel blockers, morphine sulfate
42
dose of metoprolol
25-50 mg q6hrs
43
dose of morphine
2-5 mg IV every 5- 30mins as needed
44
initial treatment for NSTE ACS
1. aspirin, 2. P2Y12 inhibitor: clopidogrel or ticagrelor; 3. anticoagulant: enoxaparin, fondaparinoux, bivalirudin, 4. GP Iib/IIIa receptor inhibitor in high risk patient fot early invasive strategy: epitifibatide or tirofiban
45
During hospitalization. Medically treated.
aspirin, P2Y12 inhibitor, anticoagulant.
46
During hospitalization. PCI treated
aspirin, P2Y12 inhibitor, anticoagulant, GP Iib/IIIa inhibitor
47
Long term. Medically treated
aspirin and clopidogrel for 12 months
48
long term. PCI treated
aspirin and clopidogrel for 12 months
49
oral antiplatelets
aspirin, clopidogrel, prasugrel, ticagrelor
50
intravenous antiplatelet
abciximab, eptifibatide, trifiban, cangrelor
51
anticoagulants
UFH, enoxaparin, fondaparinaux, bivalirudin
52
Dose prasugrel
loading pre PCI: 60 mg then 10 mg OD
53
Dose ticagrelor
Loading 180 mg then 90 mg BID
54
dose aspirin
325 mg nonenteric formulation then 75-100 mg OD
55
dose clopidogrel
300-600 mg loading dose then 75 mg OD
56
dose abciximab
0.25 mg/kg bolus then 0.125 ug/kg per min for 12-24 hr
57
max dose of abciximab
10 ug/min
58
dose of eptifibatide
180 ug/k bolus then 10 min later second bolus of 180 ug/kg then 2 ug/kg per min for 72-96 hr following first bolus
59
dose of tirofiban
25 ug/k per min then 0.15 ug/kg per min for 48-96 hrs
60
dose of cangrelor
30 ug/kg followed by 4 ug/kg per min
61
dose of enoxaparin
1 mg/kg SQ q12hrs
62
when to dose adjust enoxaparin
CrCl less than 30 ml/min
63
renal dose of enoxaparin
1 mg/kg SQ OD
64
dose of fondaparinaux
2.5 mg SC OD
65
dose of bivalirudin
0.75 mg/kg bolus then 1.75 mg/kg per hour
66
dose of UFH
Bolus 70-100 U/Kg followed by infusion of 12-15 U/Kg per hour titrated to ACT250-300 s
67
max bolus of UFH
5000 U
68
target ATC in UFH
250-300 s
69
potent reversible P2Y12 inhibitor
ticagrelor
70
genetic variant that leads to inadequate response to clopidogrel
P450 2C19
71
intravenous direct and rapidly activing P2Y12 inhibitor
cangrelor
72
indirect factor Xa inhibitor
fondaparinux
73
most important adverse effect of all antithrombotic agents
excessive bleeding
74
when to do immediate invasive strategy for patients with NSTE ACS
refractory angina, signs or symptoms of heart failure or new or worsening mitral regurgitation, hemodynamic instability, sustained ventricular tachycardia or ventricular fibrillation
75
when is immediate invasive
Within 2 hr
76
when is early invasive
Within 24 hrs
77
when is delayed invasive
Within 25-72 hrs
78
when to do early invasive
Grace score more than 140; temporal change in troponin, new ST segment depression
79
when to do delayed invasive
eGFR less than 60, EF less than 40%, early postinfarction angina, PCI within 6 months prior, GRACE score 109-140 or TIMI score than 2
80
what is the target LDL-C
less than 70 mg/dL
81
severe ischemic pain that usually occurs at rest and is associated with transient ST segment elevation
Prinzmetal variant angina
82
what causes prinzmetal variant angina
focal spasm of an epicardial coronary artery with resultant transmural ischemia and abnormalities in left ventricular function
83
diagnostic hallmark of Prinzmetal variant angina
coronary angiography demonstrates transient coronary spasm
84
main therapeutic agents for prinzmetal variant angina
nitrates and calcium channel blocker
85
most dangerous manifestation of ischemic heart disease
ACS
86
most common cuase of nontraumatic chest pain presenting in the ER
gastrointestinal
87
True or false. Myocardial ishcemic discomfort does not radiate to the trapezius muscle
True.
88
Differential if the chest pain radiates to the trapezious muscle
pericarditis
89
Canadian Cardiovascular Society Functional Classification. Experiences limitation in physical activity. Chest heaviness when climbing more than 1 flight of stairs
CCS III
90
Canadian Cardiovascular Society Functional Classification. Angina present with strenuous or rapid or prolonged exertion at work or recreation
CCS I
91
Canadian Cardiovascular Society Functional Classification. Comfortable at rest but walking more than two blocks on the level and climbing more than 1 flight of stairs at normal pace and in normal condition
CCS II
92
Canadian Cardiovascular Society Functional Classification. Marked limitation in ordinary physiscal activity. Walking one block on the level and climbing one flight of stairs causes angina
CCS III
93
Canadian Cardiovascular Society Functional Classification. Inability to carry on any physical activity without discomfort. Anginal syndrome may be present at rest
CCS IV

Cardiology (14 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions